Moreover, loss of the Alox5 gene impaired LSCs and prevented CML development [156] while activation of the PKC-β/Alox5 axis promoted BCR-ABL1-independent TKIs resistance in CML [115]. The gene discussed is PRKCB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.